Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Politics for Pros- moderated -- Ignore unavailable to you. Want to Upgrade?

To: IC720 who wrote (769403)	10/12/2022 7:34:46 AM
From: IC720	4 Recommendations Recommended By didjuneau isopatch Maple MAGA Winfastorlose Respond to of 794250

"Tulsie Gabbard who has been a breath of fresh air since bursting onto the national political fray (who, according to Hillary, is a Russian asset) is leaving her 20 year stint in the Democraptic party. Curiously, she did not anounce a switch to the Republican party. Are we about to witness the possibility of another party on deck? A 3rd party? And if one counts the MAGA folks, a 4th party? The last attempt to break the two-party stranglehold that made a real dent was H. Ross Perot. Curiouser and curiouser. Her announcement speech is one for the ages, a 1/2 hour worth the time, IMO. How soon will the censors ban it all? Remains to be seen, but it seems that the platforms are particularly allergic to truth - - and she really lays it out!!!! zerohedge.com (Scroll down for the video) If you're really pressed for time, here is the one minute version. armstrongeconomics.com *******

To: IC720 who wrote (769403)

10/12/2022 12:23:55 PM

From: Winfastorlose

2 Recommendations

Recommended By
IC720
isopatch

Read Replies (3) | Respond to of 794250

"Come into my parlor" said the demon rat spider to the deplorable MAGA fly. "We don't want any of that cancer now, do we?"

Question: Will the "personalized cancer vaccine" you receive have anything to do with your social credit score or any other "undesirable" factor?

Moderna Inc (NASDAQ:MRNA) shares are trading higher Wednesday after the company announced Merck & Company Inc (NYSE:MRK) has exercised its option to jointly develop and commercialize a personalized cancer vaccine (PCV).

The PCV, mRNA-4157/V940, will be jointly developed and commercialized by the two companies pursuant to the terms of their existing collaboration and license agreement. mRNA-4157/V940 is currently being evaluated in combination with KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant treatment for patients with high-risk melanoma.

"We have been collaborating with Merck on PCVs since 2016, and together we have made significant progress in advancing mRNA-4157 as an investigational personalized cancer treatment used in combination with KEYTRUDA," said Stephen Hoge, president of Moderna.

"With data expected this quarter on PCV, we continue to be excited about the future and the impact mRNA can have as a new treatment paradigm in the management of cancer."

Merck will pay Moderna $250 million in the third quarter to exercise its option for personalized cancer vaccines. Moderna and Merck will share costs and any profits equally under the collaboration.

See Also: Nasdaq, S&P Futures Surge Ahead of FOMC Minutes, September Inflation Prints — PepsiCo, Tech And Chinese Stocks In Focus

MRNA Price Action: Moderna has a 52-week high of $249.42 and a 52-week low of $115.03.

The stock was up 8.74% at $131.28 Wednesday morning, according to Benzinga Pro.